TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06219317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is provided in a 10 ml glass vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: standard saline solution
Study: NCT03584737

Intervention type: DIAGNOSTIC_TEST
Intervention: bacterial culture
Description: Quantitative bacterial culture assay with isolate identification by MALDI-TOF.

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR assay
Description: Semiquantitative real-time PCR assay
Study: NCT05642026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non steroidal anti-inflammatory drug and opioids
Description: Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non steroidal anti-inflammatory drug and opioids
Description: Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
Study: NCT05055791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1903
Description: SYHX1903 tablets, orally, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1903
Description: SYHX1903 tablets, orally, qd
Study: NCT06484192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 Mg
Description: participants will receive Naproxen (500 mg) to take for 7 days after surgery as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: participants will receive Ketorolac (15 mg) immediately after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 mg Oral Tablet
Description: participants will receive OxyCODONE (5 mg) to take for 7 days after surgery as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaxalone 800 MG
Description: participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaxalone 800 MG
Description: participants will receive Metaxalone (800 MG) to take for 7 days after surgery as needed
Study: NCT05923359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple Watch
Description: Apple Watch
Study: NCT04920201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stair ascent with GEMS-H with assist mode
Description: Stair ascent with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incline walking with GEMS-H with assist mode
Description: Incline walking with GEMS-H with assist mode (30 min per session, at least 3 times per weeks, total 10 sessions)
Study: NCT05862350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy inhalation with lavender essential oil
Description: patients in the experimental group will receive aromatherapy inhalation by 4 drops of 50% lavender essential oil，which is diluted with coconut essential oil， on the cotton chip in the diffuser clip for 8 hours each night during sleep

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aromatherapy inhalation with coconut essential oil.
Description: patients in the experimental group will receive aromatherapy inhalation by 4 drops of 100% coconut essential oil on the cotton chip in the diffuser clip for 8 hours each night during sleep
Study: NCT05221151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
Study: NCT05305196

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric-focused exercises
Description: Three eccentric-focused exercises:~1. Shoulder external rotator eccentric contraction in shoulder abduction 90 degree~2. Shoulder external rotator eccentric contraction in shoulder abduction 0 degree~3. Shoulder abductor eccentric contraction in shoulder abduction 90 degree

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: 1. Modified sleeper stretch~2. Modified cross-body stretch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: 1. Modified sleeper stretch~2. Modified cross-body stretch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot pack
Description: Hot pack application on shoulder region

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack
Description: Hot pack application on shoulder region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage for upper trapezius

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Massage for upper trapezius
Study: NCT06104033

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: For the procedure, the drug-coated balloon (Agent®, Boston Scientific, USA) that can be used for both de-novo coronary lesions and in-stent restenosis lesions is used.

Intervention type: DEVICE
Intervention: drug-eluting stent
Description: When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.

Intervention type: DEVICE
Intervention: drug-eluting stent
Description: When using drug-eluting stents, the latest 2nd generation drug-eluting stent (Synergy®, Boston Scientific, USA) should be used in accordance with the latest guidelines.
Study: NCT06174714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)
Description: 4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.
Study: NCT05808049

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MXP22 (Probiotic and antioxidant capsule)
Description: Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Microcrystalline Cellulose)
Description: Dose: NLT 4 Billion CFU/Capsule Route: Oral Administration Regimen: 1 capsule to be taken once daily after lunch for 120 days
Study: NCT05748912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic bronchoscopy for removal of mucus plugs
Description: Research participants that meet the study inclusion criteria will undergo a research bronchoscopy to remove airway mucus plugs from 1 lung for the first 5 participants, and, if single lung mucus removal is well tolerated, on both lungs for the next 5 participants.
Study: NCT05221151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: before spinal anaesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: before spinal anaesthesia
Study: NCT05240482

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ST36 acupuncture
Description: ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST36 acupuncture
Description: ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure the cun, defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed).
Study: NCT06383585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oZTEo
Description: An FDA approved MRI pulse sequence, oZTEo, will be added to a standard of care MRI examination. The oZTEo pulse sequence will be anonymized and sent to GE Healthcare for the application of a deep learning algorithm, 3D DL.
Study: NCT04416321

Intervention type: DEVICE
Group type: OTHER
Intervention: Surgery with the Keos Lumbar Interbody Fusion Device
Description: All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis
Study: NCT04823429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity-interval training (HIIT)
Description: Subjects performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.~Without any exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity-continuous (MICT)
Description: Subjects performed MICT (sustained 60%VO 2max) on a bicycle ergometer for 30 min/day, 5 days/week for 6 weeks.
Study: NCT05221151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 4 MG
Description: before spinal anaesthesia
Study: NCT06406907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequency Blood Flow Restriction Training Group
Description: Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Frequency Blood Flow Restriction Training Group
Description: Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Frequency Blood Flow Restriction Training Instability Group
Description: Subjects allocated to this group will perform squat exercise 6 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Frequency Blood Flow Restriction Training Instability Group
Description: Subjects allocated to this group will perform squat exercise 3 days per week for 2 weeks with 40% of arterial occlusion pressure and 30% of 1RM while standing on an unstable surface.~Blood flow restriction band will be applied at the most proximal part of the thigh. Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: The subjects of this group will perform squat exercise 6 days a week but without BFR. Pneumatic cuff will be wrapped around the thigh of the subjects but it would not be inflated.~Each subject will perform 75 repetitions in total across 4 sets of squats in the order of 30-15-15-15. Rest between sets would be 30 sec. Subjects will be instructed to tummy tuck while performing the exercise.
Study: NCT06205303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (Video)
Description: Patient decision aid on thyroxine replacement is a video designed to assist the hypothyroid adults with under-replacement. It provides clear and balanced information about hypothyroidism, the role of thyroxine, treatment benefits, potential risks, and factors interfering thyroxine absorption and bioavailability. The PDA aims to empower patients to engage in shared decision-making with their healthcare provider, ensuring they understand the options and can make choices aligned with their preferences and values.
Study: NCT05928000

Intervention type: DRUG
Intervention: Bulevirtide
Description: BulevIrtide treatment in patients with chronic hepatitis D
Study: NCT06011941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified laparoscopic transcystic biliary drainage
Description: First, a needle was passed through a separate skin puncture wound 3 cm below the costal margin on the midaxillary line/posterior axillary line. Second, a lateral incision into the cystic duct was performed medially to allow insertion and embedding of the catheter. Third, a 7-Fr catheter was introduced through the abdominal wall via the cystic duct into the CBD. Fourth, if the position of the catheter inside the CBD was correct (the end of the tube reached the distal CBD but did not pass the papilla), the lateral incision of the cystic duct was closed by a V-Loc closure device using a single-layered, continuous suture in a circling manner to simultaneously cover and anchor the C-tube. After the procedure, an artificial fistula of 3 to 5 mm in length was formed.
Study: NCT05389930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC-dominant cannabis
Description: Smoked cannabis with 9.53% THC and 0.09% CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC-dominant cannabis
Description: Smoked cannabis with 9.53% THC and 0.09% CBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBD-dominant cannabis
Description: Smoked cannabis with 0.35% THC and 11.27% CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD-dominant cannabis
Description: Smoked cannabis with 0.35% THC and 11.27% CBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis placebo
Description: Smoked placebo cannabis plant material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis placebo
Description: Smoked placebo cannabis plant material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Drink containing 0.3 g/kg of alcohol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol
Description: Drink containing 0.3 g/kg of alcohol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Drink containing 0.3 g/kg of alcohol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Placebo beverage contains only juice and a negligible trace of alcohol for masking
Study: NCT06136975

Intervention type: DEVICE
Intervention: Low-level laser therapy
Description: The treatment was once a week for eight weeks. The patient was in a supine position. The gain medium of the laser was Gallium-Aluminum-Arsenide. The laser was introduced into vagina via a silicon vaginal probe inserted by a doctor for 30 minutes (wavelength 660nm, power density 18.17mW/cm2, energy density 0.018J/cm2s, total energy density 32.4J/cm2).
Study: NCT05389930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alcohol placebo
Description: Placebo beverage contains only juice and a negligible trace of alcohol for masking
Study: NCT06194123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crest Daily Whitening Serum
Description: one week's use of Crest Daily Whitening Serum as described on the label.
Study: NCT05389930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol placebo
Description: Placebo beverage contains only juice and a negligible trace of alcohol for masking
Study: NCT05225870

Intervention type: GENETIC
Group type: OTHER
Intervention: immunohistochemical staining
Description: sections from colorectal carcinoma will be immunohistochemically stained by anti-Cortactin antobody.
Study: NCT04830072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief AWARD advice and active referral to somking cessation services
Description: The AWARD advice includes: (1) Ask about smoking history; (2) Warn about the high risk of smoking; (3) Advise to quit or reduce smoking as soon as possible; (4) Refer smokers to smoking cessation services (with a referral card); (5) Do it again: to repeat the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief AWARD advice and active referral to somking cessation services
Description: The AWARD advice includes: (1) Ask about smoking history; (2) Warn about the high risk of smoking; (3) Advise to quit or reduce smoking as soon as possible; (4) Refer smokers to smoking cessation services (with a referral card); (5) Do it again: to repeat the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat-based support through Instant Messaging apps
Description: Participants in the intervention group will receive 3 months of chat-based support through Instant Messaging apps (e.g., WhatsApp, WeChat). The support mainly includes (1) regular messages on health warnings, benefits and methods of quitting, coping craving approach, and promotion to use the SC services; (2) real-time, personalized, and interactive behavioral and psychosocial support through Instant Messaging apps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chat-based support through Instant Messaging apps
Description: Participants in the intervention group will receive 3 months of chat-based support through Instant Messaging apps (e.g., WhatsApp, WeChat). The support mainly includes (1) regular messages on health warnings, benefits and methods of quitting, coping craving approach, and promotion to use the SC services; (2) real-time, personalized, and interactive behavioral and psychosocial support through Instant Messaging apps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leaflet
Description: Leaflet on harms of smoking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: Leaflet on harms of smoking

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AR images
Description: AR images of the harms of smoking and the benefit of abstinence.
Study: NCT05556447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet delivered pain coping skills training
Description: Participants in the intervention group will complete 8 weeks of pain coping skills training delivered online
Study: NCT04763057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoPUTTY MTA
Description: NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium hydroxide
Description: Calcium hydroxide the gold standard for IPT
Study: NCT06472596

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha
Description: compare results of investigations in asthmatics and non asthmatics

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC, CRP ,ESR, ABG , interleukin 6, tumor necrotic factor alpha
Description: compare results of investigations in asthmatics and non asthmatics
Study: NCT05973448

Intervention type: OTHER
Group type: OTHER
Intervention: Novel Lighting Condition
Description: Horizontal and vertical lights over a doorway visible from the bed

Intervention type: OTHER
Group type: OTHER
Intervention: Novel Lighting Condition
Description: Horizontal and vertical lights over a doorway visible from the bed

Intervention type: OTHER
Group type: OTHER
Intervention: Novel Lighting Condition
Description: Horizontal and vertical lights over a doorway visible from the bed

Intervention type: OTHER
Group type: OTHER
Intervention: Novel Lighting Condition
Description: Horizontal and vertical lights over a doorway visible from the bed

Intervention type: OTHER
Group type: OTHER
Intervention: Control Lighting Condition
Description: Standard night light plugged into wall socket

Intervention type: OTHER
Group type: OTHER
Intervention: Control Lighting Condition
Description: Standard night light plugged into wall socket
Study: NCT04820842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching tablets.
Study: NCT05551377

Intervention type: OTHER
Group type: OTHER
Intervention: Head-up tilt sleeping
Description: Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head-up tilt sleeping
Description: Whole-body head-up tilt sleeping (HUTS) will be carried out in three different angles, each for the duration of two weeks. Prior to the first angle the participant will sleep in a horizontal position for 1 week. The different angles will be installed using a wedge between the mattress and bed frame.